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Phosphorylation of-synuclein (-syn) at Ser-129 is ahallmark
of Parkinson disease and related synucleinopathies. However, the
identity of the natural kinases and phosphatases responsible for
regulating-synphosphorylation remainunknown.Herewedem-
onstrate that three closely relatedmembersof thehumanPolo-like
kinase (PLK) family (PLK1, PLK2, andPLK3) phosphorylate-syn
and-syn specifically at Ser-129 and Ser-118, respectively. Unlike
other kinases reported to partially phosphorylate-syn at Ser-129
in vitro, phosphorylationbyPLK2andPLK3 is quantitative (>95%
conversion).OnlyPLK1andPLK3phosphorylate-synatSer-118,
whereas no phosphorylation of -syn was detected by any of the
four PLKs (PLK1 to -4). PLK-mediated phosphorylation was
greatly reduced in an isolated C-terminal fragment (residues 103–
140) of -syn, suggesting substrate recognition via the N-terminal
repeats and/or the non-amyloid component domain of -syn. PLKs
specifically co-localized with phosphorylated Ser-129 (Ser(P)-129)
-syn in various subcellular compartments (cytoplasm, nucleus, and
membranes) ofmammalian cell lines and primary neurons as well as
in -syn transgenic mice, especially cortical brain areas involved in
synapticplasticity. Furthermore,we report that the levelsofPLK2are
significantly increased in brains of Alzheimer disease and Lewy body
disease patients. Taken together, these results provide biochemical
and in vivo evidence of -syn and -syn phosphorylation by specific
PLKs. Our results suggest a need for further studies to elucidate the
potential role of PLK-syn interactions in the normal biology of these
proteinsaswell as their involvement in thepathogenesisofParkinson
disease andother synucleinopathies.
Increasing evidence suggests that phosphorylationmay play an
important role in the oligomerization and fibrillogenesis (1), Lewy
body formation (1, 2) and neurotoxicity of-synuclein (-syn)5 in
vivo (3). The majority of -syn within Lewy bodies (LBs) in dis-
eased human brains and animalmodels of Parkinson disease (PD)
and related synucleinopathies is phosphorylated at Ser-129
(Ser(P)-129) (1, 2, 4–7). Although recent studies support the
notion that phosphorylation at Ser-129 is related to pathology and
blocks -syn fibrillization in vitro (8, 9), the exact mechanisms by
which phosphorylation at Ser-129 modulates -syn aggregation
and toxicity in vivo remain elusive. Unraveling the role of phos-
phorylation inmodulating the physiological andpathogenic activ-
ities of -syn requires identification of the kinases and phospha-
tases involved in regulating its phosphorylation in vivo.
Several kinases that phosphorylate -syn at serine and tyro-
sine residues, primarily in its C-terminal region, have been
identified using in vitro kinase assays and co-transfection stud-
ies. Casein kinase I and II, G-protein-coupled receptor kinases
(GRK1, GRK2, GRK5, and GRK6), and calmodulin-dependent
kinase II (10–12) phosphorylate -syn at Ser-129. Ser-87 is the
only residue outside the C-terminal region reported to undergo
phosphorylation by casein kinase I (12) and the dual specificity
tyrosine-regulated kinase 1A (13). Tyrosine phosphorylation
has also been reported at Tyr-125 by Fyn (14), Syk (15), Lyn
(15), c-Frg (15), and Src (16) tyrosine kinases, with Syk (15) also
phosphorylating at Tyr-133 and Tyr-136.
The Polo-like kinases (PLKs) comprise a family of conserved
Ser/Thr protein kinases that play key roles in cell cycle regula-
tion, cellular response to stress, and carcinogenesis. In mam-
malian cells, the PLK family consists of three closely related
kinases PLK1, PLK2/Snk (serum-inducible kinase), PLK3/Fnk
(fibroblast growth factor-inducible kinase) also designated Prk
(proliferation-related kinase), and a distant member PLK4/Sak
(Snk akin kinase) (17–21). The four PLKs share a conserved
sequence motif characterized by two regions: a highly con-
served N-terminal serine/threonine catalytic domain and a
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C-terminal non-catalytic termed the Polo box domain (PBD)
(Fig. 1) (22, 23). The PBD plays important roles in regulating
substrate interactions, targeting, subcellular localization, and
autoinhibition of the PLKs (24). The PBD of PLK1, PLK2, and
PLK3 contain two tandem Polo boxes (80 residues in length)
that associate to form a phosphopeptide binding site, whereas
PLK4 possesses only a single PB, which mediates the dimeriza-
tion of PLK4, resulting in a structure that resembles the PBD of
the other PLKs (24–26).
Recent reports demonstrate that -syn is phosphorylated
by PLK2 (27, 28). In this report, we confirm these find-
ings and demonstrate for the first time, using in vitro kinase
assays, co-transfection, and small interference RNA
(siRNA)-mediated knockdown of PLKs, that - and -, but
not -syn are phosphorylated by specific members of the
PLK family. PLK phosphorylation of synucleins occurs
specifically at Ser-129 in -syn and Ser-118 in -syn and
appears to be mediated by specific interactions between the
PLKs and the N-terminal region (residues 1–95) of syn.
These findings were validated by colocalization of -syn
and PLKs in different subcellular
compartments and co-transfection
studies as well as siRNA-mediated
knockdown of PLKs in mammalian
cells and primary neurons. PLK2
and PLK3 partly co-localized with
Ser(P)-129 -syn in primary hip-
pocampal neurons as well as in cor-
tical brain areas of -syn transgenic
mice. Furthermore, we demonstrate
that the level of neuronal PLK2 is
elevated in the Alzheimer disease
(AD) and Lewy body disease (LBD)
brains and correlates with the
increased levels of Ser(P)-129 in
these brains compared with healthy
controls. Together, our findings
point to PLK2 and PLK3 as the pri-
mary PLKs responsible for -syn
phosphorylation and highlight the
importance of further studies to elu-
cidate the potential role of the inter-
actions between the PLKs and-syn
and their implications for -syn
aggregation and toxicity in PD and
other synucleinopathies.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purifica-
tion of Proteins—pCMV6-Entry-
PLK1 (PLK1), pCMV6-Entry-PLK2
(PLK2), pCMV6-Entry-PLK3 (PLK3)
and pCMV6-Entry-PLK4 (PLK4)
open reading frame clones of hu-
man PLKs were from OriGENE
and provided as Myc/DDK-tagged
plasmids. pAAV-CMV--syn wild
type (WT) (-syn) was kindly pro-
vided by Patrick Aebischer’s laboratory (Brain Mind Institute,
Ecole Polytechnique Federale de Lausanne). The-syn deletion
mutant (73–83) and the /-syn chimera (-syn-(1–72)/-
syn-(73–83)/-syn-(73–134)) were kindly provided by Prof.
Michel Goedert (Medical Research Council Laboratory of
Molecular Biology, Cambridge, UK) (29). All constructs
were confirmed by DNA sequencing (Mycrosynth, Switzer-
land) using the primers provided by the supplier. Recombi-
nant PLK enzymes were purchased from Intvitrogen and
Cell Signaling Technologies. All recombinant -syn proteins
and mutants used in this study were expressed as described
previously (8).
Unless otherwise specified, the following antibodies were
used in this study: anti-human PLK1 (sc-5585), anti-human/
rodent PLK2 H-90 (sc-25421), and anti-human -syn (clone
211) antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). Anti-human PRK (PLK3) (BD 556518) were purchased
from BD Pharmigen. Anti-Ser(P)-129 -syn was from Wako,
-actin antibody was from Abcam (Cambridge, MA), and goat
anti-mouse Cy3 was from (GE Healthcare).
FIGURE 1. Schematic depiction of the sequences of synucleins and PLK1s-4. A, schematic depictions illus-
trating the sequence similarities and differences among the four PLKs andmembers of the synuclein family of
proteins. The four members of the PLK family share a conserved N-terminal kinase domain. The PBD of PLK1,
PLK2, and PLK3 contain two tandemPolo boxes (80 residues in length) that associate to formaphosphopep-
tide binding site, whereas PLK4 possesses only a single PB, which mediates the dimerization of PLK4.
B, sequence alignment of the human WT -, -, and -syn generated by the Clustal 2.0.8 multiple sequence
alignment program. Ser-129 in -syn and Ser-118 are highlightedwithin the square. aa, amino acids.
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Preparation of -Syn C-terminal Fragment—WT -syn in 50
mM Tris, 150 mM sodium chloride, pH 7.6, was trypsinized at a
concentration of 3 mg/ml and a mass ratio of -syn/trypsin
(PromegaCorp.,Madison,WI) of 100:1. The reactionwas incu-
bated at 37 °C for 24 h to generate the C-terminal fragment
(residues 103–140). TheC-terminal fragmentwas then purified
by size exclusion chromatography and using a Superdex 75 HR
10/30 column (GE Healthcare).
In Vitro Kinase Assay—WT or mutant -syn was phosphory-
lated by PLK1 to -4 (Cell Signaling Technologies and Invitro-
gen) at a concentration of 1.44 mg/ml (100 M), unless other-
wise stated. The phosphorylation reactions were carried out in
the presence of 1.09mMATP (Sigma), 1 reaction solution (20
mM HEPES, 10 mM MgCl2, 2 mM DDT, pH 7.4), and 1 g of
PLK, 144 g of -syn at 30 °C for 15 min to 24 h. The reactions
were quenched with EDTA disodium salt (25 mM final concen-
tration) (Axon Lab, AG, Le Mont-Sur-Lausanne, Switzerland).
The progress of the reaction was monitored by matrix-assisted
laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF MS) (30).
Real-time NMR Spectroscopy—NMR samples contained
0.1mM 15N-labeled-syn in 200mMHEPES, 10mMMgCl2, 2
mM dithiothreitol, and 1.09 mM ATP, pH 6.9. The real-time
assay was started by the addition of kinase into the NMR sam-
ple, with a protein/kinase ratio of 100:0.5g.NMRexperiments
were acquired on a Bruker Avance 600-MHz NMR spectrom-
eter. NMR data were processed by Bruker TOPSPIN version
2.0. To allow for efficient phosphorylation, the temperaturewas
set to 303 K. To reduce the impact of signal broadening due to
amide proton exchange, the temperature was lowered to 288 K
during the measurement of 1H,15N heteronuclear single quan-
tum coherence (HSQC) spectra. In the case of PLK3, the phos-
phorylation reaction proceeded very rapidly at 303 K. There-
fore, we also followed the kinetics of phosphorylation of -syn
by PLK3 at 293 and 288 K using 0.075 mM -syn (protein/
kinase 100:0.5 g). Backbone resonance assignments of WT
and phosphorylated -syn were obtained previously. The
degree of phosphorylation at Ser-129 was calculated from the
intensity of the NMR signals of phosphorylated and unphos-
phorylated Ser-129. Errors were estimated based on the signal/
noise ratio in the NMR spectra.
MALDI-TOF MS—MALDI calibrants were from Sigma, tri-
fluoroacetic acid was from Pierce, and sinapinic acid was from
Fluka. 3-l aliquots of in vitro PLK-phosphorylated -syn were
reserved for the MALDI analysis. The samples were diluted
1:10 in 0.1% trifluoroacetic acid and further mixed with an
equal volume of 14 mg/ml sinapinic acid solution in 0.1% tri-
fluoroacetic acid, ACN (1:1). 0.5 l of this solution was depos-
ited on the mirror-polished target and analyzed with a 4700
MALDI-TOF/TOF instrument (Applied Biosystems Inc., Fos-
ter City, CA). The spectra were calibrated on the pseudomo-
lecular peak of cytochrome c, apomyoglobin, ubiquitin, and
-syn preparedwith the samematrix and deposited close to the
samples.
Cell Culture and Transient Transfection—Human Embry-
onic Kidney cells (HEK 293T) and immortal cell lines from
HeLa were grown in Dulbecco’s modified Eagle’s medium
(Invitrogen AG, Basel, Switzerland) supplemented with 10%
fetal bovine serum and 5% penicillin/streptomycin in a
humidified incubator, 5% CO2, 37 °C. For HEK 293T cells,
transient transfection was performed on 6-well plates at a cell
confluence of 70–80%, using the standard calcium phosphate
(CaPO4) transfection protocol. For HeLa cells, transient trans-
fection was performed employing LipofectamineTM 2000
(Invitrogen AG, Basel, Switzerland) according to the manufac-
turer’s instructions. The overall amount of plasmid used was
4 g/well.
PLK2 and PLK3 Small Interfering RNA (siRNA) Silencing—
ON-TARGET siRNA sequence targeting human PLK2
5-GGACATGGCTGTGAATCAG-3 (57) and ON-TARGET
siRNA sequence targeting human PLK3 5-CGGCCTCAT-
GCGCACATCC-3 (58) as well as non-targeting (ON-
TARGET siControl) were purchased from Dharmacon (Lafay-
ette, CO). HeLa cells were grown at a density of 200,000 cells/
well and transfected the day after with increased concentration
of each siRNA independently using LipofectamineTM 2000
according to the manufacturer’s instructions. Cells were
treated with siRNA for 48 h followed by transient transfection
with -syn WT using LipofectamineTM 2000 for an additional
24 h before analysis byWestern blot and immunofluorescence.
For silencing in primary neurons, hippocampal neuronswere
prepared from P0 Sprague-Dawley rats (Charles River/Iffa
Credo, L’Arbresle Cedex, France) as described previously by
Steiner et al. (31) and were plated at a density of 200,000 cells/
35-mm dish (Falcon, BD Biosciences) in growthmedium (min-
imum Eagle’s medium, 20 mM glucose, 0.5 mM glutamine, 100
units/ml penicillin, 100g/ml streptomycin, 10%horse serum).
Neuron’s medium is kept, and the cells were transfected for 2 h
at day 12 with a 60 nM concentration of each murine PLK2 and
PLK3 siRNA (sc-39153 and sc-39151, respectively, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) using LipofectamineTM
2000 reagent (Invitrogen) following the manufacturer’s
instructions. Neurons were then reincubated in their own and
previous media for 72 h. For biochemical analysis by Western
blotting, the cells were lysed with in a buffer containing Hepes
(0.02 M), EGTA (0.02 M), EDTA (0.02 M), KCl (0.1 M), dithio-
threitol (0.1 M), and 1% Triton X-100. The lysate was centri-
fuged at 20,000 g for 15 min, and the supernatant was recov-
ered and analyzed immediately by Western blotting or stored
immediately at80 °C.
Subcellular Fractionation—HEK 293T cells were transiently
transfected with PLK1 to -3 and -synWT for 24 h. Subcellular
fractionation was carried out employing the subcellular pro-
teome extraction kit (Calbiochem) according to the manufac-
turer’s instructions. The fractions were analyzed by Western
blot, and the purity was evaluated using control antibodies pro-
vided as subcellular markers of cell compartment, including
cytosolic, membrane/particulate, and nucleus (anti-Hsp90,
anti-calnexin, and anti-PARP-1, respectively).
SDS-PAGE and Immunoblot—Cells were harvested 24 h
post-transfection, and total homogenate was prepared by lysis
in a buffer containing 150 mM NaCl, 1 mM EDTA, 20 mM Tris,
pH 7.40, 0.5% Nonidet P-40, enriched with a 1:200 protease
inhibitor mixture (Sigma), 1 mM phenylmethylsulfonyl fluoride
(Sigma), and 1 M okadaic acid (Acros). Cleared lysates were
obtained by centrifugation at 14,000 rpm, 4 °C for 20min. 10g
Synucleins Phosphorylation by PLKs
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of total protein diluted in loading buffer were separated on
1-mm, 12% SDS-PAGE. The proteins were then transferred to
nitrocellulose membrane using the iBlotTM dry blotting system
(Invitrogen AG, Basel, Switzerland) for 7 min. The membrane
was then probed overnight with the primary antibody after 30
min of blocking inOdyssey blocking buffer (Li-Cor Biosciences
GmbH) diluted 1:3 in phosphate-buffered saline (Sigma). After
four timeswasheswith PBST (phosphate-buffered saline, 0.01%
(v/v) Tween 20 (Sigma)), the membrane was incubated for 1 h
with secondary antibody (goat or rabbit Alexa Fluor 680 IgG)
protected from light at room temperature. The immunoblot
was finally washed four times with PBST and three times with
phosphate-buffered saline and scanned in a Li-COR scanner at
a wavelength of 700 nm.
Subcellular Localization and Immunocytochemistry in Pri-
mary Neurons—For immunocytochemistry, hippocampal rat
neurons were prepared as described (32). Hippocampal neu-
rons (200,000 cells in a 35-mm2 dish) were cultured on cover-
slips (12mm;VWR) coatedwith poly-D-lysine (BDBiosciences)
and laminin mouse (Invitrogen) and fixed for 12 min at room
temperature in a freshly prepared solution (pH 7.4) containing
4% paraformaldehyde and 4% sucrose in phosphate-buffered
saline. Neurons were then washed three times in MTBS buffer
(66 mM NaCl, 100 mM Tris-HCl, pH 7.4) and then incubated
overnight with the first antibody in buffer A containing 5% nor-
mal goat serum, 5%normal horse serum, 3%bovine serumalbu-
min, 0.3% Triton X-100 in MTBS for overnight at 4 °C. The
following day, cultures were rinsed three times in MTBS and
incubated in the buffer A containing goat anti-mouse Cy3 cou-
pled (1:1000; Jackson ImmunoResearch, West Grove, PA) or
goat anti-rabbit Alexa Fluor 488 coupled as secondary anti-
body (IF 1:500; Molecular Probes Inc.) for 2 h at room temper-
ature.After threewashes inMTBS, coverslipsweremounted on
glass slides with 4,6-diamidino-2-phenylindole-Vectashield
medium (Vector) and imaged with a Zeiss LSM510 confocal
microscope.
Immunostaining of Mouse Brain Sections—(Thy1)-[A30P]-
syn mice were sacrificed by cervical dislocation. Brains were
dissected and fixed in 4% paraformaldehyde in phosphate
buffer (pH 7.4). The fixed brains were embedded in paraffin,
and 4-m-thick sections were cut on a microtome. Serial sec-
tions were directly transferred onto SuperFrost Plus coverslips,
incubated overnight at 60 °C, and paraffin-decorated with
xylene. Rehydration was performed over a descending ethanol
series: 100, 95, and 75% Tris-buffered saline, pH 7.4 (TBS). Per-
oxidase activity was eliminated by treatment with 1% H2O2 in
TBS for 30 min, followed by three washes in TBS. Antigen
retrieval was carried out by heating the sections up to 90 °C in
citrate buffer (pH 6.0) for 30 min, followed by a cooling step of
15 min on ice. Blocking was done in 5% goat antiserum in TBS
for 30 min at room temperature. Incubation with rabbit mono-
clonal antibody against human Ser(P)-129 -syn (1:500;
Abcam) and anti-PLK2 or anti-PLK3 (1:50; both from Santa
Cruz Biotechnology, Inc.) was performed in TBS containing 2%
goat antiserum at 4 °C overnight. Subsequently, the sections
were washed and incubated at room temperature with biotiny-
lated goat anti-rabbit antibody followed by the avidin-biotin
complex (VECTASTAIN ABC kit). For visualization, Vector
SG-Blue was used followed by nuclear staining with Nuclear
Fast Red for 5 min and short rinsing under tap water. Sections
were thendehydrated (ethanol 75%, 95%, 100%, and xylene) and
mounted with Pertex. Photomicrographs were taken with an
Axioplan 2 imagingmicroscope (Carl Zeiss) and processedwith
AxioVision version 4.3 imaging software.
Human Samples and Tissue Processing—Analysis of -syn
phosphorylation was performed with post-mortem human
temporal cortex samples. The human samples were obtained
from theAlzheimer’sDisease ResearchCenter at theUniversity
of California San Diego. A total of 18 cases were included, of
which six were non-demented controls, six were diagnosed as
AD, and six were diagnosed as LBD. Cases of LBDwere defined
based on the clinical presentation of dementia and the patho-
logical findings of LBs in the locus coeruleus, substantia nigra,
or nucleus basalis of Meynert as well as in cortical and subcor-
tical regions. LBs were detected using hematoxylin/eosin anti-
ubiquitin and anti--syn antibodies as recommended by the
Consortium on LBD. In all cases, the brains were processed
within 8 h after death. Brains were divided sagitally, and the
right hemibrain was serially sectioned and preserved at70 °C
forWestern blot analysis. To analyze the distribution and levels
of -syn, PLK2, and PLK3 in the brains of patients with AD and
LBD, samples from the temporal cortex were homogenized and
fractioned into cytosolic and membrane fractions by ultracen-
trifugation. Approximately 20 g of protein/well were loaded
into 4–12% BisTris gels with MOPS/SDS buffer and blotted
onto polyvinylidene difluoride membranes. Blots were incu-
bated overnight with antibodies against PLK2 and PLK3
(1:1000; Invitrogen), Ser(P)-129 -syn (WAKO), and -syn
(1:1000; Chemicon, Temecula, CA), followed by secondary
antibodies tagged with horseradish peroxidase (1:5000; Santa
Cruz Biotechnology, Inc.). Immunoreactivity was visualized by
enhanced chemiluminescence and analyzed with a Versadoc
XL imaging apparatus (Bio-Rad). Analysis of actin levels was
used as a loading control.
RESULTS
To determine whether -syn is a substrate for members of
the PLK family of kinases (PLK1, PLK2, PLK3, and PLK4), we
performed in vitro kinase assays using purified recombinant
-syn together with each of the four PLKs, and co-transfection
experiments in mammalian cells (human embryonic kidney
HEK 293T, HeLa and SH-SY5Y neuroblastoma cells).
PLK1 to -3 Phosphorylate -Syn Specifically at Ser-129 in
Vitro—To assess the phosphorylation of -syn by the PLKs,
-syn (100 M) was incubated with either of the four kinases at
1 g of PLK, 144 g of -syn. The reactions were incubated at
30 °C, and the extent of phosphorylation was monitored by
MALDI-TOFmass spectrometry. Upon incubation with PLK1,
PLK2, and PLK3, we observed a shift in the molecular mass of
-syn by 80 Da (from 14,462 to 14,542 Da) for PLK1, -2, and -3,
which corresponds to the addition of one phosphate group (Fig.
2). A closer examination of Fig. 2A demonstrates that PLK2,
and PLK3 phosphorylate -syn quantitatively, whereas 60–
70% conversion was observed for PLK1 (Fig. 2A). No other
kinase has been observed (data not shown) or reported to phos-
phorylate -syn with the same efficiency. The MALDI-TOF
Synucleins Phosphorylation by PLKs
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results suggest that PLK1 to -3 phosphorylate -syn at a single
site. To determine if PLK1 to -3-mediated phosphorylation
occurs at Ser-129, the phosphorylation reactions were analyzed
byWestern blotting using an antibody against Ser(P)-129-syn
and subjected to trypsin digestion and peptide mapping by
MALDI-TOF and liquid chromatography-electrospray ioniza-
tion MS/MS. -Syn samples incubated with the PLK1 to -3
showed a band at 14 kDa that was detectable with both anti--
syn and anti-Ser(P)-129 antibodies (Fig. 2B). Comparative anal-
ysis of the tryptic fragments of these bands revealed that phos-
phorylation of -syn occurs only within peptide fragments that
encompass Ser-129. Trypsin digestion resulted in a peptide
with amolecular mass of 4353.0 Da (MH) corresponding
to the monophosphorylated C-terminal fragment 103–140
containing Ser-129 (calculated mass 4272.4 Da (M) (NEEG-
APQ EGILEDMPVDPDNEAYEMPpSEEGYQDYEPEA, where
pS represents phosphoserine) (data not shown). This peptide
fragment does not contain other serine or threonine residues,
suggesting that phosphorylation indeed occurs at Ser-129. To
further confirm these results, in vitro phosphorylation was also
performed with a mutant that cannot be phosphorylated at
position 129, S129A. As predicted, none of the PLKs could
phosphorylate S129A mutant -syn (data not shown).
Real-time Spectroscopy of the Phosphorylation Reaction—
Hetereonuclear NMR spectroscopy on 15N-labeled protein
modified by PLK allows identification of all phosphorylation
sites, measures the level of integration, and yields kinetic data
for the enzymaticmodification of the individual sites. Although
FIGURE 2. In vitro phosphorylation of synucleins by PLK1 to -4. A, MALDI-TOF analysis of the WT -syn after phosphorylation by PLK1 to -4. For PLK1 to -3,
there is an 80-Da increase in the molecular mass of WT -syn (14,461 80 14,541), corresponding to one phosphorylation. B, Western blot analysis of the
same samples in A. The anti-Ser(P)-129 antibody detected a band, suggesting that the phosphorylation detected by mass spectrometry is at position 129.
C, comparison of two-dimensional 1H,15N HSQC spectra of unphosphorylated WT (green) and -syn phosphorylated by PLK3 (red). A dashed rectanglemarks
glutamine (Q) and asparagine (N) side chain resonances. D, kinetics of in vitro phosphorylation of Ser-129 in -syn by PLK3 (black), PLK2 (red), and PLK1 (blue)
asmonitoredby real-timeNMRspectroscopy.NMRsamples contained0.1mM15N-labeled-syn in 200mMHEPES, 10mMMgCl2, 2mMdithiothreitol, and1.09
mM ATP, pH 6.9. The real-time assay was started by the addition of kinase into the NMR sample using a protein/kinase ratio of 100:0.5 mg. The error barswere
determined based on the signal/noise ratio observed in the NMR spectra.
Synucleins Phosphorylation by PLKs
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the reaction mixture is complex with enzyme, ATP and -syn,
filtering through the 15N label allows the monitoring of the
kinase activity in the NMR tube without any further sample
purification. To obtain single-residue resolution and identify all
potential phosphorylation sites, the enzymatic reactionwas fol-
lowed by two-dimensional 1H-15N heteronuclear correlation
spectra. Phosphorylated serine and threonine residues are
readily detected because phosphorylation shifts their amide
proton resonance downfield 8.8 ppm, to an empty region of the
15N--synHSQC spectrum (Fig. 2C). The real-timeNMRassay
was applied to PLK1, PLK2, and PLK3. In the case of PLK3, the
peak of phosphorylated Ser-129 was clearly observed already
after 45 min (Fig. 2D). With increasing incubation time, the
intensity of the NMR signal of phosphorylated Ser-129
increased. Quantitative analysis of the increase of the NMR
signal of phosphorylated Ser-129 indicated that PLK3 fully
phosphorylates -syn within 2.5 h under the conditions of the
assay (Fig. 2D). Importantly, no additional NMR signals of
phosphorylated residues appeared, indicating that PLK3 exclu-
sively phosphorylated -syn at Ser-129. In the case of PLK1, no
phosphorylation of -syn could be detected during the time
course of the experiment. The significantly reduced PLK1
phosphorylation of -syn in the NMR experiments, compared
with the in vitro kinase assay, is most likely due to the fact that
the NMR phosphorylation experiments were performed at
lower temperature (15 °C versus 30 °C for in vitro kinase assays)
to reduce the impact of signal broadening due to amide proton
exchange. Real-time spectroscopy of -syn phosphorylation by
PLK2 showed that PLK2 phosphorylates -syn only at Ser-129.
However, the kinetics of the enzymatic reaction is significantly
slower for PLK2 than for PLK3, and -syn was not fully phos-
phorylated at the end of the assay.
- and-SynbutNot-SynArePhosphorylatedbyPLK1 to -3—
To evaluate the specificity of PLKs for-syn, we also performed
in vitro phosphorylation employing purified - and -syn.
-Syn is a 134-amino acid-long protein sharing 61% sequence
homology with -syn. The sequence homology of the two
synucleins is more prominent in their N-terminal regions
(90% sequence similarity) (33). -Syn is 127 amino acids long
and shares 55.9 and 54.3% sequence homology with -syn and
-syn, respectively (34) (Fig. 1B). Unlike -syn, both - and
-syn are not found in LBs (35). As illustrated in Fig. 3, incuba-
tionwith PLK1 and PLK3 resulted in quantitative conversion of
-syn into its monophosphorylated form, as evidenced by the
shift of the -syn molecular mass,m/z, from 14,291 to 14,369.7
Da. A minor (5%) second peak corresponding to diphosphory-
lated -syn (m/z 14,448) was also detected under these con-
ditions. Using an anti-Ser(P)-118 antibody generated in our
laboratory and trypsin digestion and peptidemapping (data not
shown),we showed thatPLK1- andPLK3-mediatedphosphory-
lation of -syn occurs at Ser-118 (Fig. 3B). We did not observe
any detectable phosphorylation of -syn by PLK2. Interest-
ingly, all four PLKs failed to phosphorylate -syn in vitro. These
differences may reflect differences in substrate specificity
among the four PLKs (Fig. 3C) and/or suggest that PLK-medi-
ated phosphorylation of synucleins involves specific interac-
tions between the various kinases and specific domains in
synucleins.
Specificity of -Syn Phosphorylation by PLK1 to -3—In-
trigued by the lack of phosphorylation of -syn by PLK2, we
sought to determine the sequence determinants of- and-syn
by the PLKs. More specifically, we tried to assess if the differ-
ences in phosphorylation efficiency are due to 1) the sequence
divergence between  and -syn; 2) differences in the substrate
specificity of the PLKs as determined by the amino acid residues
flanking the phosphorylated serine residue; 3) specific protein-
protein interaction; or 4) differences in the conformational
properties of the two proteins. -Syn and -syn share high
sequence homology at the N- and C-terminal region and differ
mainly in the fact that -syn lacks residues 73–83 in the non-
amyloid component (NAC) region of -syn, suggesting that
NAC region is important for synuclein interactions and phos-
phorylation by PLKs. To determine if phosphorylation by the
PLKs is mediated by protein-protein interactions involving the
N-terminal region of-syn (residues 1–102), we first generated
a C-terminal fragment of -syn comprising residues 103–140,
which contains the PLK phosphorylation site, Ser-129. All four
PLKs failed to efficiently phosphorylate 103–140 -syn. Only
minor phosphorylation was observed in the case of PLK2 and
PLK3 (Fig. 4A). This finding further suggested that the N-ter-
minal and NAC regions of -syn might influence the efficiency
of the PLK1 to -3 phosphorylation. It is also plausible that-syn
interaction with the PLKs is mediated by specific conforma-
tions of the C terminus that only exist in the full-length protein.
To test these hypotheses, we investigated the in vitro phos-
phorylation of an -syn mutant lacking residues 73–83 within
the NAC region (-syn-(73–83)), which are absent in -syn
(Fig. 4B). Removal of these residues did not have an effect on
Ser-129 phosphorylation by PLK1, PLK2, and PLK3 as dis-
cerned byMALDI-TOF andWestern blotting analysis using an
anti-Ser(P)-129 antibody (Fig. 4, A and C). Similarly, the incor-
poration of theseNAC residues into corresponding sites within
-syn (-syn-(1–72)/-syn-(73–83)/-syn-(73–134)), called
/-syn(1) in this study, did not significantly influence the
levels of phosphorylation at Ser-118 by all three PLKs (Fig. 4, A
and D). These findings suggest that the absence of 73–83 in
-syn is not sufficient to explain the lack of phosphorylation by
PLK2 and that the NAC region may not play an important role
in modulating -syn phosphorylation by PLK1 to -3.
To further test this hypothesis and probe the effect of other
regions within -syn, we evaluated the effect of various muta-
tions in the N-terminal, NAC, and C-terminal regions of -syn
on the PLK1 to -3 phosphorylation efficiency. Mutations at
Ser-87 (S87A and S87E) abolished phosphorylation by PLK1,
whereas phosphorylation by PLK2 and PLK3 was not affected
(supplemental Figs. 1 and 2). To confirm these findings, we
investigated the phosphorylation ofmouse-syn by PLK1 to -4.
Mouse -syn shares high (	94%) sequence homology with
human WT -syn, and their sequence differences are mostly
located in the NAC and C-terminal regions (residues 83, 87,
100, 103, 107, 121, and 122), including a serine3 asparagine
mutation at position 87 (S87N). These mutations appear to
reduce PLK1-mediated phosphorylation of -syn without
influencing phosphorylation by PLK2 and PLK3 (supplemental
Fig. 3). The effect of mutations at the C terminus of -syn was
also assessed. Mutating Ser-129 to alanine blocked the phos-
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phorylation by PLK1 to -3. In addition, mutations near Ser-129
alter the specificity of the three kinases, because only PLK2 was
observed to phosphorylate E126A (supplemental Fig. 3C).
In Vitro Phosphorylation of Fibrillar -Syn by PLK1 to -4—
Whether phosphorylation at Ser-129 occurs prior to or after
-syn fibrillization and LB formation in vivo remains unclear.
Recent studies byWaxman andGiasson (36) and our laboratory
demonstrated that fibrillar -syn is a better substrate for casein
kinase I phosphorylation. To determine whether -syn fibrils
are good substrates for phosphorylation by PLKs, we generated
fibrils of WT -syn and subjected them to in vitro phosphory-
lation with PLK1 to -4. Briefly, WT -syn was aggregated at a
concentration of 200–400Mat 37 °Cwith continuous shaking
for 24–72 h. The fibrils formed were harvested by centrifuga-
tion, sonicated, and phosphorylated at a concentration of 100
M as described above. As shown in Fig. 5, the efficiency of in
vitro phosphorylation of -syn fibril was as follows: PLK3 	
PLK2 	 PLK1. As is the case with monomeric -syn, PLK1
exhibited decreased phosphorylation activity toward fibrillar
-syn relative to PLK2 and PLK3.
PLK Phosphorylation of -Syn inMammalian Cell Lines and
Primary Neurons—Having established that PLK1 to -3 phos-
phorylate -syn at Ser-129 in vitro, we then sought to deter-
mine whether -syn phosphorylation by PLKs occurs in mam-
malian cells. HEK 293T and HeLa were co-transfected with
expression vectors encoding -syn and PLK1, -2, -3, or -4.
Western blot analysis of cell lysates demonstrated that PLK2
and PLK3, but not PLK4, phosphorylate -syn at Ser-129 (Fig.
6A). Onlyminor phosphorylation by PLK1was detected in both
cell lines. Quantification of the Ser(P)-129 bands in Fig. 6A
demonstrates that PLK2 is more efficient in phosphorylating
-syn in these cell lines (Fig. 6B). Similar results were obtained
in SH-SY5Y cells (data not shown). Interestingly, co-transfec-
tion of -syn with PLK1, -2, -3, or -4 in HEK 293T cells and
HeLa resulted in significant phosphorylation at Ser-118 by
PLK1, PLK2, and PLK3, with PLK2 showing the highest effi-
FIGURE 3. Recombinant -syn is phosphorylated by PLK1 and PLK3, whereas -syn does not undergo phosphorylation by PLK1 to -4. A, MALDI-TOF
analysis of the in vitro phosphorylation reaction of WT - and -syn by PLK1 to -4. WT -syn undergoes phosphorylation by PLK1 and PLK3 but not PLK2 and
PLK4. None of the recombinant PLKs were observed to phosphorylate -syn in vitro. B, Western blot analysis of -syn samples phosphorylated by PLK1 to -4,
using our anti-phosphoserine 118 (pS118) antibody. The table in C shows the consensus substrate specificity of PLK1 to -4 (, hydrophobic amino acid) and the
amino acids adjacent to the Ser-129 in -syn and its equivalent residues in - and -syn.
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ciency in phosphorylating -syn in vivo (Fig. 6C), in contrast to
the in vitro results (Fig. 3). The lack of phosphorylation of-syn
by PLK2 in vitro suggests that other factor(s)within the cellmay
influence the conformation of -syn and/or its interactions
with PLK2 in a manner that results in significant enhancement
in Ser-118 phosphorylation by PLK2 in the cell.
Subcellular Localization of -Syn and PLK1 to -3—To deter-
mine whether the level of phosphorylation correlates with the
degree of colocalization of -syn and the PLKs, the expression
and subcellular localization of -syn, PLKs, or -syn co-trans-
fected with PLK1, PLK2, or PLK3 was assessed by subcellular
fractionation,Western blotting, and immunocytochemistry on
non-transfected HeLa cells (Fig. 7). Western blot analysis
revealed that PLK1, PLK2, PLK3, and -syn were strongly
enriched in the cytosolic and membrane fractions. PLK1 and
PLK3 were also highly enriched in the nuclear fraction relative
to PLK2, although the level of nuclear PLK2 seemed to increase
in cells co-transfected with -syn (Fig. 7A). The colocalization
of -syn with PLK2 or PLK3 correlated well with an increase in
Ser(P)-129.Despite the increased expression and colocalization
of -syn and PLK1 in the cytosolic, membrane, and nuclear
fractions, the level of Ser(P)-129 in these fractionswasminimal.
These findings are consistent with the results from the in vitro
FIGURE 4. Removal of the entire N-terminal residues (positions 1–103) abolishes Ser-129 phosphorylation, whereas deletion of the NAC residues
73–83 has no effect on Ser-129 phosphorylation by PLK1 to -3. A, MALDI-TOF analysis of the PLK-phosphorylated 1–103 -syn, 73–83 -syn, and
chimeric -syn(1) proteins. B, schematic representation of theWT - and -syn, deletion -syn73–83 and chimeric -syn(1) proteins. C, Western blotting
analysis of the in vitro phosphorylation of these constructs at Ser-129 by PLK1 to -4 using anti Ser(P)-129 antibody (1:5000; Wako).D, Western blotting analysis
of the PLK-phosphorylated WT and chimeric -syn(1) probed with Ser(P)-118 antibody (1:250) (1000 ng/lane). a.a., amino acids.
FIGURE 5. In vitro phosphorylation of-syn fibrils by PLK1 to -4. Top, pre-
formed - fibrils were incubated with recombinant PLKs in the appropriate
reaction buffers, and phosphorylation at Ser-129was assessed by anti-Ser(P)-
129 antibodies. Bottom, quantification of the level of Ser(P)-129 signal nor-
malized against -syn and -actin (pS118/(-syn  actin)), n 3.
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kinase assays (Fig. 2) and co-transfection experiments (Fig. 6)
and suggest that PLK2 might phosphorylate -syn throughout
the cell, whereas PLK3 phosphorylates cytosolic and nuclear
-syn. PLK1 does not contribute significantly to Ser-129 phos-
phorylation, at least in HEK 293T, HeLa, and SH SY5Y cells.
Interestingly, we have consistently observed that constitutively
phosphorylated -syn (Ser(P)-129) is localized primarily in the
nucleus (Fig. 7B). These findings are consistentwith the nuclear
distribution of -syn (37) and with recent studies demonstrat-
ing nuclear enrichment of Ser(P)-129 immunostaining in HEK
293T cell as well as in aged and young presymptomatic mice
overexpressing -syn (38). In these studies, the specificity of
nuclear localization of Ser(P)-129was further verified using dif-
ferent anti-Ser(P)-129 antibodies and treatments with phos-
phatases (38).
siRNA-mediatedGene Silencing of PLK2 and/or PLK3Results
in Significant Reduction (50–60%) in Ser-129 Phosphoryla-
tion in Cell Lines and Primary Neurons—In order to determine
the relative contribution of PLK2 and PLK3 to the phosphory-
lation of endogenous -syn at Ser-129, we silenced each kinase
in HeLa cells and primary neurons using siRNA against human
and mouse PLKs, respectively. Given the low levels of endog-
enously expressed cytosolic -syn in HEK 293T andHeLa cells,
the levels of Ser(P)-129 were measured and quantified by
immunofluorescence using anti-Ser(P)-129-specific antibod-
ies. These results provide ameasure of only nuclear Ser(P)-129.
To determine the consequences of
siRNA-mediated gene silencing of
PLK2 and/or PLK3 on total Ser(P)-
129 levels, the siRNAs were intro-
duced 48 h prior--syn transfection
in HeLa cells.
Upon silencing of PLK2 or PLK3
in HeLa cells, we observed 45–
50% reduction in the levels of
endogenous Ser(P)-129 in the nu-
cleus as quantified by immunofluo-
rescence using an anti-Ser(P)-129
antibody (Fig. 8A). Given the effi-
ciency of both kinases in phos-
phorylating -syn, we thought that
silencing both kinasesmight be nec-
essary to abolish phosphorylation at
Ser-129. Interestingly, silencing of
both kinases did not result in further
reduction in nuclear Ser(P)-129 sig-
nal. These findings are consistent
with our subcellular fractionation
results and previous studies (39)
demonstrating significant nuclear
localization of PLK3 and PLK1 but
not PLK2. Transient overexpression
of-syn results in increased levels of
nuclear and cytoplasmic Ser(P)-129
in cell lines, including HeLa and
HEK 293T, thus facilitating the
detection of Ser(P)-129 by Western
blot analysis. Interestingly, when we
examined the effect of silencing either kinases on transiently
expressed -syn byWestern blotting, we observed greater than
60% reduction in Ser(P)-129 levels (Fig. 8, B and C). Together,
these findings demonstrate that PLKs contribute significantly
to nuclear and cytoplasmic Ser-129 -syn phosphorylation.
The fact that wewere not able to abolish Ser(P)-129 levels upon
siRNA-mediated knockdown of each kinase or both kinases
suggests that other kinases are involved in modulating the
phosphorylation of nuclear and cytoplasmic -syn at this resi-
due and/or incomplete knockdown efficiency.
PLK1 to -3 Phosphorylate -Syn Specifically at Ser-129 in
Primary Neurons—To further evaluate the relevance of these
findings in neurons,we investigated the expression of PLK2 and
PLK3 and their subcellular localization with respect to -syn
and Ser(P)-129-syn. In addition to their prominent role in cell
cycle regulation, the PLKs are also expressed to different levels
in postmitotic cells, including neurons. Interestingly, we
observed that constitutively phosphorylated -syn is localized
primarily in the nucleus of primary hippocampal neurons (Fig.
9A), consistent with the observations made in cell lines (Fig.
7B). Among the two PLKs, PLK2 yielded strong signals and
colocalization to the nucleus of primary rat neurons with
Ser(P)-129. PLK3 was distributed homogeneously in hip-
pocampal neurons with low expression levels in the nucleus.
More strikingly, we found that Ser(P)-129 colocalized at a lower
level with PLK3 than with PLK2 in the nucleus (Fig. 9A). Simi-
FIGURE 6. Phosphorylation of -syn and -syn by PLKs in mammalian cells (HEK-293T and HeLa). A, the
cells were co-transfected with pAAV-CMV--syn-WT and different pCMV6-E`ntry-PLKs and lysed 24 h post-
transfection. The expression level of PLKs and-synphosphorylation at Ser-129weredetectedby immunoblot
using antibodies against FLAG tag and anti-Ser(P)-129. B, quantification of the level of Ser(P)-129 signal inten-
sitywasnormalizedagainst total fluorescence signal of-synWTand-actin (Ser(P)-129/(-syn-actin),n
3. C, expression of -syn-WT and Ser(P)-118 in HEK 293T and HeLa cells after co-transfection as previously
described was detected by Western blot (data not shown), and quantification of the level of -syn Ser(P)-118
signal intensity was normalized against the total fluorescence signal of-syn-WT and-actin (pS118/(-syn
-actin), n 3.
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larly, PLK2 co-localized with Ser(P)-129 in neuronal nuclei and
cell bodies in hippocampal and cortical brain areas, whereas
PLK3 showed a distinct neuropil staining (Fig. 9, A and B).
To assess phosphorylation of Ser-129-syn by PLK1 to -3, hip-
pocampal primary neuronswere transfectedwith different siRNA
targeting RNA coding for PLK1, PLK2, and PLK3. We observed
that PLK2 and PLK3 are the major PLKs contributing to Ser-129
phosphorylation.We quantified the part of each PLK in the phos-
phorylation at Ser-129. Compared with the control (Fig. 9C), we
found that PLK2 and PLK3 knockdown decrease by 63 and 58%,
respectively, the total amount of Ser(P)-129, indicating that they
are the major kinase involved in phosphorylation of endogenous
-syn. Moreover, we observed that the decrease of the protein
level of each PLKmodifies neither the levels of expressions of the
otherPLKsnor the total amountof-synas shownby theconfocal
imaging and byWestern blot analysis (Fig. 9D). These results sug-
gest that PLK-mediated phosphorylation of-syn at position Ser-
129 strongly involves PLK2 and PLK3.
PLK2 and PLK3 Expression in Mouse Model of Sy-
nucleinopathy—To investigate the relationship of -syn phos-
phorylation with PLKs in vivo, we performed immunostaining
on brain sections derived from -syn transgenic (Thy1)-
FIGURE 7. Subcellular localization of -syn and PLKs in mammalian cell. A, HEK 293T cells were co-transfected with pAAV-CMV--syn-WT and different
pCMV6-E`ntry-PLKs and then subjected to subcellular fractionation24–48hpost-transfectionwith theProteoExtract subcellular proteomeextraction kit from
Calbiochem. Purified fractions were then immunoblotted with corresponding antibodies. PARP1, Hsp90, and calnexin proteins were used as control for the
nuclear, cytosolic, and membrane particulate fractions, respectively. B, confocal microscopy of HeLa cells co-stained with anti-Ser(P)-129 and anti--syn
antibodies. Endogenous Ser(P)-129 (red) accumulate exclusively in the nucleus stainedwith 4-6-diamidino-2-phenylindole (Dapi), whereas-synWT (green)
is mostly membrane and cytosolic in non-transfected cells (NT).
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[A30P]-syn, which develop age-dependent -synucleinopa-
thies that can be labeled with anti-Ser(P)-129-specific antibod-
ies (5, 38, 40, 41). In these mice, PLK2 and PLK3 were widely
distributed throughout the brain. PLK2 and PLK3 were gener-
ally localized diffusely in the neuropil. In addition, some neuro-
nal subpopulations showed enriched somal and nuclear immu-
nostainings for PLK2 and PLK3, respectively. In the
hippocampus, PLK2 was weakly immunostained in scattered
neuronal cell bodies throughout the cornu ammonis, whereas
PLK3 showed a more diffuse staining pattern in the neuropil
(Fig. 10,A–D). By comparison, Ser(P)-129 immunoreactivity in
old mice was very strong in CA1, weak in CA3, and barely
detectable in CA2 (Fig. 10E). Interestingly, we noted the pres-
ence of PLK3 and Ser(P)-129 immunoreactivity in neuronal cell
bodies in the subiculum (Fig. 10, D and E). In the neocortex,
there was a very similar staining pattern for non-classical
somal/nuclear Ser(P)-129 immunostaining (38) and both PLK2
antibodies, whereas PLK3 showed almost exclusive neuropil
staining in superficial cortical layers (Fig. 10, F–J). The tend-
ency of PLK2 to co-localize with Ser(P)-129 in neuronal nuclei
and a more cytosolic/neuritic distribution of PLK3 is in accor-
dance with the hippocampal neuron culture staining (Fig. 9).
None of the PLK antibodies used here specifically immuno-
stained the Lewy-like Ser(P)-129 neuropathology in the brain
stem of old (Thy1)-[A30P]-syn mice (Fig. 10, K–O). Two dif-
ferent anti-PLK2 showed the cortical somal/nuclear localiza-
tion (Fig. 10, G and H) and its absence in brain stem neuropa-
thologies (Fig. 10, L and M), and antibody neutralization
reduced the anti-PLK2 staining in
the neuropil completely and in cell
bodies to a good extent (Fig. 10,A, F,
and K), indicating specificity of the
immunostaining.
Collectively, these results suggest
that PLK2 may contribute to some
physiological -syn phosphoryla-
tion in cortical brain areas. Up-reg-
ulation of CA3 Ser(P)-129 in old
transgenic mice might involve fur-
ther, post-translational activations
of PLKs and/or additional kinases
(priming or additive). As for the
pathological -syn kinase, the lack
of co-localization in Lewy neurites
in this mousemodel raises the spec-
ulation that neuropil PLK3 might
phosphorylate -syn in the synapse,
and after that retrogradely trans-
ported Ser(P)-129 -syn fibrilizes
within axon (Lewy neurites) and
neuronal cell bodies (Lewy bodies).
Cross-breedings with PLK knock-
out mice and long term treatments
with specific PLK inhibitors are nec-
essary to answer these questions
and determine to what extent these
kinases, and more specifically Ser-
129 phosphorylation, contribute to
the neuropathological processes in synucleinopathies. Further
studies are required to determine whether Ser-129 phosphory-
lation in the nucleus is mediated primarily by members of the
PLK family or selectively translocated from the cytoplasmupon
phosphorylation by PLKs and other kinases.
PLK Levels Are Elevated in AD and LBD Brains—In order to
determine the physiological and pathological relevance of Ser-
129 phosphorylation by PLKs, we sought to assess the levels of
PLK2 and PLK3 in human brain (temporal cortex) homoge-
nates from non-demented controls and AD and LBD cases.
Compared with controls, in the LBD, there was an increase in
the levels of PLK2 immunoreactivity in the neurons (Fig. 11A).
In the AD cases, there was also an increase in PLK2 immuno-
reactivity but to a lesser extent compared with the LBD cases
(Fig. 11, A and B). By immunoblot analysis we confirmed the
presence of PLK2 and the specificity of the antibody at detect-
ing a doublet band at an estimatedmolecular mass of 62 kDa in
the membrane fractions (Fig. 11C). However, immunoblot
analysis did not reveal any significant differences in the levels of
PLK2 in control versus AD and LBD cases (Fig. 11C). In addi-
tion to its localization in neurons, PLK2 appears to be highly
enriched in the processes in the neuropil, where it is highly
enriched. When performing the image analysis, it is possible to
differentiate the levels of PLK2 in the different diseased tissues
by immunocytochemistry, but by immunoblotting this is
more difficult because of all the PLK2 in the neuropil, which
might have a dilutional effect, thus masking the differences
observed by immunocytochemistry (Fig. 11D). In the case of
FIGURE 8. Silencing of PLK2 and PLK3 results in significant reduction of Ser(P)-129 levels in HeLa cell.
A, detection of nuclear Ser(P)-129 in non-transfected cells and cells transfectedwith 100 nMON-TARGET siRNA
PLK2 and 100 nM ON-TARGET siRNA PLK3. Quantitative analysis of total Ser(P)-129 fluorescence of individual
cells was normalized against 4,6-diamidino-2-phenylindole (Dapi) intensity, n  3. B and C, immunoblot
analysis of crude lysate fromHeLa cells sequentially transfected with -syn and siRNA PLK2 and siRNA PLK3 at
the indicated concentration. Anti--actin was used as a control of the total amount of proteins loaded.
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PLK3, we tested several commercial antibodies but failed to
identify an antibody that allows for specific and reliable
detection of PLK3 in human brain tissues by immunohisto-
chemistry and immunoblotting.
DISCUSSION
Several post-translational modifications of -syn have been
described, including phosphorylation, nitration, ubiquitina-
tion, and truncations, but the role of these modifications in
modulating the physiologic and/or pathological properties of
-syn remains poorly understood.One can speculate thatmany
-syn properties and functions are regulated by its interactions
with other proteins and its subcellular localization/targeting,
which in turn might be regulated by post-translational mod-
ifications. Therefore, identifying the key molecules respon-
sible for regulating -syn post-translational modifications
and elucidating their mechanism of action are essential for
unraveling the molecular basis of -syn function(s) in health
and disease.
Herewe showedusing in vitro kinase assays that- and-syn
but not -syn are phosphorylated by members of the PLK fam-
ily of Ser/Thr protein kinases. Phosphorylation of - and -syn
occurs primarily on Ser-129 and Ser-118, respectively. Interest-
ingly, neither -, - or -syn appear to be a substrate for PLK4.
PLK4 is significantly larger (970 amino acids) than PLK1 to -3
(Fig. 1A) and contains only one PBD, which is essential for
PLK4 dimerization (24, 26) (Fig. 1A). Given the reported roles
of Polo box domains in modulating the subcellular localization
of PLKs (42) and the interactions of PLKs with their substrates,
it is tempting to propose that the PBD in PLK1 to -3 plays a
critical role in modulating the interactions -syn phosphoryla-
tion by PLK1 to -3. However, our results suggest that the pro-
pensity of PLKs to phosphorylate -syn is determined by their
substrate specificity and sequence complementarities between
the catalytic site of each kinase and the amino acid sequence
flanking the phosphorylated serine residue as well as the con-
formation of the protein. Sequence analysis and three-dimen-
sional homology modeling studies revealed that PLK2 and
PLK3 show the highest pairwise identity of the catalytic domain
andATPbinding site. The sequence identity betweenPLK2 and
PLK3 at the catalytic domain and ATP binding site is 68 and
97%, and that of PLK2 and PLK3 to PLK1 is53 and 86–90%,
respectively (43). Furthermore, the consensus sequences of
PLK2 and PLK3 are very similar and characterized by the pres-
ence of acidic residues within the 3–4 residues flanking the
phosphorylation site ((D/E)X(S/T)(D/E), where  denotes a
hydrophobic amino acid). PLK1 to -3 have a preference for
substrates in which at least one of the three residues flanking
the serine residue is negatively charged. Both - and -syn ful-
fill this criterion (Fig. 3C). This charge distribution on the sub-
strates complements the electropositive distribution on the
substrate binding sites of PLK1 to -3. PLK4, which lacks the
preference for acidic residues, has much reduced electroposi-
tive environment in its substrate biding site. The lack of phos-
phorylation of -syn by the PLKs can also be explained by its
sequence divergence from -syn and -syn. The amino acids
flanking the equivalent serine residue in -syn are alanine (1-
FIGURE 9. Silencing of PLK2 and PLK3 significantly inhibit-syn phosphorylation at Ser-129 in primary neurons. Shown is colocalization (first panel) of
Ser(P)-129 and PLKs (A) or WT -syn versus PLKs (B). C, Western blot analysis of total cell homogenate from 72-h silencing of PLKs in hippocampal neurons.
D, quantification of Ser(P)-129 fluorescence signal relative to control (from non-transfected cells). Data are expressed as the mean
 S.D; bar, 100 M; n 3.
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position) and lysine (1-position), thus explaining the lack of
phosphorylation by PLK1 to -4.
Although -syn is phosphorylated by PLK1, PLK2, and
PLK3, only PLK1 and PLK3 were observed to phosphorylate
-syn in vitro. -Syn and -syn share high sequence homology
at the N- and C-terminal region and differ mainly in the fact
that -syn lacks residues 73–83 in the NAC region of -syn,
suggesting that these residuesmight be important for synuclein
interaction and phosphorylation by PLKs. To test this hypoth-
esis, we investigated the effect of removal of the entire N-ter-
minal region 1–102 or the NAC region 73–83 on PLK-medi-
ated phosphorylation of -syn. In addition, we examined the
ability of the PLKs to phosphorylate a chimeric construct, in
which the NAC domain comprising residues 73–83 has been
reintroduced to -syn, /-syn(1). Interestingly, removal of
the entire N-terminal domain
1–102 abolished Ser-129 phosphor-
ylation by all three PLKs 1–3,
whereas removal of the NAC
domain 73–83 did not have a signif-
icant effect on Ser-129 phosphory-
lation by the PLKs. Similarly, the
introduction of the NAC domain
73–83 derived from -syn into
-syn did not change the level of
phosphorylation and/or specificity
of PLKs toward-syn. BothWTand
chimeric -syn undergo phosphor-
ylation by PLK1 and PLK3 but not
PLK2. Our observations that PLK2
phosphorylates -syn in HEK 293T
and HeLa cells suggest that other
factor within the cell may influence
the conformation of -syn and/or
its interactions with PLKs. The
potential role of the conformational
state of-syn and-syn inmodulat-
ing their phosphorylation by the
PLKs is supported by our findings
that 1) mutations within the NAC
region (S87A, S87E, and S87N in
mouse -syn), which are distant
from Ser-129, result in significant
reduction in PLK1-mediated Ser-
129 phosphorylation; 2) none of the
PLKs phosphorylate the C-terminal
fragment 102–140. These findings
strongly suggest that phosphoryla-
tion at Ser-87 and/or tyrosine resi-
dues within the C terminus
(Tyr-125, Tyr-133, and Tyr-136)
would significantly influence the
efficiency and specificity of Ser-129
phosphorylation by PLKs and possi-
bly other kinases (44).
Ser-129 Phosphorylation by the
PLKsOccurs inMammalian Primary
Neurons and Human Brain—To
determine the relevance of the in vitro kinase assays, we probed
the possibility that -syn phosphorylation by the PLKs occurs
in mammalian cells and investigated the expression levels and
subcellular colocalization of -syn and PLKs in primary rat
neurons and brain tissues from symptomatic -syn transgenic
mice and human brain (temporal cortex) homogenates from
AD and LBD cases and non-demented controls.
By co-transfection of -syn and PLKs or siRNA-mediated
silencing of PLKs, we demonstrated that PLK2 and PLK3
colocalize with -syn in different cellular compartments
and are major contributors to Ser-129 phosphorylation of
endogenous and transiently expressed -syn in mammalian
cells (HEK 293T and HeLa) and primary neurons. These
findings are consistent with the results we obtained from the
in vitro kinase assays using purified recombinant -syn and
FIGURE 10. Paraffin-embedded brain serial sections from 1-year-old (Thy1)-[A30P]-SYN transgenic
mice were immunostained with BL1695 anti-PLK2 with (A, F, and K) or without (B, G, and L) preincuba-
tion with neutralizing PLK2 protein, H-90 anti-SNK/PLK2 (C, H, andM) anti-PLK3 (D, I, and N), and anti-
Ser(P)-129 (E, J, andO). Counterstaining was performed with Nuclear Fast Red. Pictures were taken from the
hippocampal region (A–E), neocortex (F–J), and brain stem (K–O). Size bars, 200 m.
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PLKs. Despite the high degree of colocalization of PLK1 and
-syn in nuclear, cytosolic, and membrane fractions, very
minimal levels of Ser-129 phosphorylation were detected
upon co-transfection of PLK1 and -syn, consistent with
observed low efficiency of PLK1 phosphorylation of -syn
in vitro (Fig. 2).
In addition to their prominent role in cell cycle regulation,
the PLKs are also expressed to different levels in postmitotic
cells, including neurons. PLK2 and PLK3 are expressed in
response to synaptic activation and appear to be involved in
synaptic plasticity, remodeling, and homeostasis (45–47) and
have been implicated in the regulation of dendritic spin mor-
phology. Moreover, a recent study using whole-genome
microarray hybridization analysis identified PLK2 as indispens-
able for nerve growth factor-driven neuronal differentiation
because its silencing inhibits neuronal differentiation (48).
However, little is known about their substrates and function in
neurons. In neurons, PLK2 and PLK3 were shown to interact
with Cib, a Ca2- and integrin-binding protein (49), SPAR
(spine-associated Rap guanosine triphosphatase-activating
protein), and the postsynaptic scaffolding protein PSD-95 (50).
Seeburg et al. (47) demonstrated that induction of PLK2 in hip-
pocampal neurons results in phosphorylation and degradation
of PSD95 and SPAR by the ubiquitin-proteasome system,
resulting in the loss of mature dendrite spines and synapse in
cell lines and primary neuron cultures. The work presented
here establishes the presynaptic proteins - and -syn as neu-
ronal substrates for PLK2 and -3 and suggest a potential role for
these kinases in modulating the normal physiology of -syn.
The physiological relevance of -syn phosphorylation by
members of the PLK family of kinases is supported by the fol-
lowing: 1) PLK2 and PLK3 partially colocalize with Ser(P)-129
-syn in mammalian cells and pri-
mary hippocampal neurons and in
cortical brain areas of mice overex-
pressing -syn; 2) siRNA-mediated
silencing of PLK2 or PLK3 results in
significant reduction of nuclear and
cytoplasmic Ser(P)-129 levels in
mammalian cells and primary neu-
rons; 3) PLK2 is expressed in normal
brain, and neuronal PLK2 is ele-
vated in AD and LBD brains, con-
sistent with previous reports dem-
onstrating increased levels of PLK in
the cytosol of vulnerable hippocam-
pal and cortical neurons and homog-
enates of AD brain compared with
control brains (51); 4) Inglis et al.
(27) identified PLK2 as a major con-
tributor to -syn phosphorylation
in vivo and showed that the level of
Ser(P)-129 in the PLK2 knock-out
mice is reduced by70%. Together,
these findings point to PLK2 and
PLK3 as the primary PLKs and
major kinases responsible for -syn
phosphorylation at Ser-129.
Implications for Elucidating the Role of Ser(P)-129 in PD
Pathogenesis—The identification of -syn as a substrate of
PLK2 and PLK3 has significant implications for understand-
ing the role of Ser-129 phosphorylation in modulating -syn
aggregation and toxicity and development of therapeutic strat-
egies to treat PD and related synucleinopathies. Previous in vivo
studies attempting to elucidate the role of Ser-129 phosphory-
lation have relied on the overexpression of phosphomimicking
mutations (S129E/D) and blocking phosphorylation (S129A)
have yielded inconclusive and/or conflicting results (52–55).
Furthermore, in vitro biophysical comparison of the phospho-
mimicking (S129E/D) mutants to Ser(P)-129 -syn revealed
that these mutations do not reproduce all aspects of phosphor-
ylation (8, 9).6 Together, these findings suggest that modeling
-syn phosphorylation in vivo can only be achieved by modu-
lating the expression and/or activity of the kinases and phos-
phatases involved. PLK2 and PLK3 are the only kinases we have
identified thus far to yield selective and quantitative phosphor-
ylation of-syn (PLK2 and -3) and-syn (PLK1 and -3) in vitro.
The specificity and efficiency with which these kinases phos-
phorylate -syn in vitro and in vivo provide unique opportuni-
ties to elucidate themolecularmechanisms and functional con-
sequences of -syn phosphorylation in vivo and validate the
potential of PLKs as therapeutic targets for treating PD and
related synucleinopathies.
Therapeutic Implications—Whether inhibition of PLK2 and
PLK3 kinase activity will increase or diminish -syn aggrega-
6 K. E. Paleologou, A. Oueslati, S. Gideo, C. C. Rospigliosi, H. Y. Kim, G. R. Lam-
berto, C. O. Fernandez, A. Schmid, F. Chegini, P. W. Gai, D. Chiappe, M.
Moniatte, B. L. Schneider, P. Aebischer,M. Zweckstetter, D. Eliezer, andH.A.
Lashuel, submitted for publication.
FIGURE 11. PLK2 expression in diseased brains (AD and LBD). A and B, immunohistochemical analysis of
levels of PLK2 in control, AD, and LBD cases. C and D, immunoblot analyses with antibodies against cytosolic
-syn, PLK2, Ser(P)-129, and actin was performed using temporal cortex homogenates from non-demented
controls, AD, and LBD cases. Total cellular protein concentrations in each sample were confirmed by compar-
ison with levels of actin (bottom). Bar graph, quantitative image analysis of both immunocytochemical and
immunoblotting results are shown.
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tion and toxicity and PD still awaits the results from in vivo
studies aimed at elucidating the consequences of selective over-
expression and/or silencing of these PLKs in the affected brain
regions on animal models of synucleinopathies. If it turns out
that phosphorylation of Ser-129 is a causative event in the
pathogenesis of PD, then inhibiting PLK2 and PLK3 would be
an attractive strategy for the treatment of PD. The PLKs,mainly
PLK1 and PLK3, have been the focus of drug discovery efforts
for the treatment of cancer. However, the use of kinase inhibi-
tors as potential drugs in PD would require the development of
potent and selective inhibitors that can cross the blood brain
barrier and target each member of the PLK family. The four
PLKs share high sequence identity (25–34%) at the kinase
domain and80% identity of the ATP binding sites. Studies by
Kothe et al. (56) suggested that subtle differences at the cata-
lytic site may offer opportunities for potent selective targeting
of PLK2. For example, the presence of Leu-132 in PLK1 and
PLK3, creates a pocket in the ATP binding site that does not
exist in PLK2 or other kinases inwhich this residue is conserved
as tyrosine. As of today, the only structural information avail-
able is derived from the x-ray structural data of the catalytic
domain of PLK1. Therefore, solving the x-ray structure of PLK2
and PLK3 may shed new light onto sequence and structural
features that could be exploited to develop selective inhibitors
targeting each of the PLKs. An alternative approach that could
allow specific modulation of PLKs activity would be to target
interactions involving the Polo box domains that are specific to
this family of kinases.
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